Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Gill, David Michael
Agarwal, Neeraj
Hahn, Andrew W.
Johnson, Eric
Poole, Austin
Carroll, Emma
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC)
    Gupta, Santosh
    Halabi, Susan
    Kemeny, Gabor
    Anand, Monika
    Nanus, David M.
    Giannakakou, Paraskevi
    George, Daniel J.
    Gregory, Simon
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).
    Bitting, Rhonda Lynn
    Healy, Patrick
    Halabi, Susan
    George, Daniel J.
    Ko, Jung Hyun
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [5] Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc)
    Caffo, O.
    Maines, F.
    De Giorgi, U.
    Fratino, L.
    Lo Re, G.
    Zagonel, V.
    D'Angelo, A.
    Donini, M.
    Verderame, F.
    Ratta, R.
    Procopio, G.
    Campadelli, E.
    Massari, F.
    Gasparro, D.
    Ermacora, P.
    Messina, C.
    Giordano, M.
    Alesini, D.
    Conteduca, V.
    Veccia, A.
    Galligioni, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 61 - 61
  • [6] The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
    Halabi, Susan
    Guo, Siyuan
    Park, Joseph J.
    Nanus, David M.
    George, Daniel J.
    Antonarakis, Emmanuel S.
    Danila, Daniel Costin
    Szmulewitz, Russell Zelig
    Mcdonnell, Donald P.
    Norris, John D.
    Lu, Changxue
    Luo, Jun
    Armstrong, Andrew J.
    CLINICAL CANCER RESEARCH, 2024, 30 (06) : 1152 - 1159
  • [7] Indicators of clinical response to abiraterone acetate (AA) men with metastatic castration-resistant-prostate-cancer (mCRPC).
    Boegemann, Martin
    Mikah, Phillip
    Eminaga, Okyaz
    Herrmann, Edwin
    Papavassills, Philipp Marius
    Semjonow, Axel
    Krabbe, Laura-Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    DRUGS, 2011, 71 (15) : 2067 - 2077
  • [9] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [10] Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Ileana, Ecaterina
    Antoun, Sami
    Albiges, Laurence
    Massard, Christophe
    Di Palma, Mario
    Escudier, Bernard J.
    Fizazi, Karim
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345